Gold Shunt Overview
The SOLX Gold Shunt is a novel, minimally invasive device that has the potential to advance the surgical treatment of glaucoma. Developed in collaboration with experienced engineers and leading glaucoma surgeons, the device is the first biocompatible, pure gold implant that uses the eye's natural pressure differential to reduce intraocular pressure (IOP). Differentiated from other surgical glaucoma options, the results are achieved without creating a bleb, a common source of serious medical complications.
The SOLX Gold Shunt is an investigational device currently being studied in a multi-center clinical trial and is not available for use in the United States. The device is currently approved for use in Canada as well as in select countries in Europe.
Key features of the SOLX Gold Shunt device include:
Safety: No bleb-related complications, highly biocompatible material
Efficacy: Novel mechanism of action, advanced engineering to optimize performance
Reproducible: Industrialized surgical procedure, familiar technique
SOLX has collaborated with leading glaucoma surgeons to develop a precise, familiar surgical technique. The end result is an industrialized and highly reproducible procedure that can be performed in an outpatient setting.
A clinical study of the SOLX Gold Shunt in patients with refractory glaucoma is currently underway in multiple centers across the US. Future studies will be aimed at assessing other unmet needs in glaucoma management and treatment.